Spyre Therapeutics Shares Plunge After RA Sub-Study Falls Short of Internal Threshold
Spyre Therapeutics shares tumbled in pre-market trading after topline data from the rheumatoid arthritis arm of its Phase 2 SKYWAY trial showed statistically significant activity but did not meet the company's internal bar to pursue SPY072 as a standalone RA treatment. The company will not advance SPY072 as monotherapy in RA, and investors sold the…